Physician profile
John Vaeth
NPI 1992848345
$2,052,815.11
in general payments reported to CMS, 2019-2025
20 companies · $466K in 2025
The $466K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134K · 2020: $127K · 2021: $198K · 2022: $307K · 2023: $409K · 2024: $412K · 2025: $466K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $848K · Travel and Lodging: $220K · Honoraria: $114K · Consulting Fee: $76K · Food and Beverage: $29K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $847,560.15 |
| Travel and Lodging | $220,183.93 |
| Honoraria | $113,725.00 |
| Consulting Fee | $75,800.00 |
| Food and Beverage | $28,839.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $709,145.34 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $383,922.74 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $364,504.57 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $208,886.71 | 2023-2025 | Auvelity |
| Allergan, INC. | $163,680.96 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $97,923.51 | 2023-2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $57,917.58 | 2020-2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $31,586.29 | 2019-2022 | |
| Tris Pharma INC | $13,792.40 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Supernus Pharmaceuticals, INC. | $11,597.54 | 2019-2022 | |
| Neos Therapeutics, LP | $3,861.99 | 2019-2022 | |
| Sage Therapeutics, LLC | $2,383.98 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $1,406.64 | 2019-2024 | Spravato |
| Aytu Biopharma, INC. | $1,071.03 | 2021 | |
| Lundbeck LLC | $739.54 | 2019-2025 | Rexulti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sentynl Therapeutics, INC. | $127.00 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $94.50 | 2023-2025 | Rexulti |
| Shire North American Group INC | $84.25 | 2019 | |
| Sunovion Pharmaceuticals INC. | $66.12 | 2019-2021 | |
| Adlon Therapeutics L.P. | $22.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vaeth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.